United Capital Financial Advisers LLC Purchases 11,621 Shares of Pfizer Inc. (NYSE:PFE)

United Capital Financial Advisers LLC lifted its holdings in Pfizer Inc. (NYSE:PFEGet Rating) by 1.3% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 884,849 shares of the biopharmaceutical company’s stock after purchasing an additional 11,621 shares during the period. United Capital Financial Advisers LLC’s holdings in Pfizer were worth $45,809,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Vident Investment Advisory LLC increased its stake in shares of Pfizer by 39.7% in the 1st quarter. Vident Investment Advisory LLC now owns 191,106 shares of the biopharmaceutical company’s stock worth $9,891,000 after purchasing an additional 54,323 shares in the last quarter. Horizon Investments LLC increased its position in Pfizer by 10.1% in the first quarter. Horizon Investments LLC now owns 206,545 shares of the biopharmaceutical company’s stock worth $10,606,000 after buying an additional 18,996 shares in the last quarter. Atria Wealth Solutions Inc. bought a new position in shares of Pfizer in the first quarter worth about $23,134,000. Capital Group Private Client Services Inc. bought a new position in shares of Pfizer in the first quarter worth about $7,959,000. Finally, Myriad Asset Management Ltd. lifted its position in shares of Pfizer by 19.0% during the 1st quarter. Myriad Asset Management Ltd. now owns 59,500 shares of the biopharmaceutical company’s stock valued at $3,080,000 after buying an additional 9,500 shares in the last quarter. Hedge funds and other institutional investors own 67.90% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Morgan Stanley lowered their price target on shares of Pfizer from $52.00 to $49.00 and set an “equal weight” rating on the stock in a report on Friday, July 8th. The Goldman Sachs Group set a $50.00 price target on Pfizer in a research note on Thursday, September 1st. UBS Group set a $59.00 price objective on Pfizer in a research report on Thursday, September 1st. JPMorgan Chase & Co. set a $57.00 target price on Pfizer in a research report on Tuesday, June 28th. Finally, Barclays set a $50.00 price target on Pfizer in a research note on Thursday, September 1st. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average target price of $57.33.

Pfizer Stock Up 1.6 %

Shares of NYSE:PFE opened at $47.84 on Friday. The company has a 50-day moving average price of $49.61 and a 200 day moving average price of $50.46. The company has a current ratio of 1.42, a quick ratio of 1.20 and a debt-to-equity ratio of 0.39. Pfizer Inc. has a 12 month low of $40.94 and a 12 month high of $61.71. The company has a market cap of $268.49 billion, a price-to-earnings ratio of 9.36, a PEG ratio of 0.59 and a beta of 0.70.

Pfizer (NYSE:PFEGet Rating) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.09. The business had revenue of $27.74 billion during the quarter, compared to analyst estimates of $26.20 billion. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. The company’s revenue for the quarter was up 46.8% on a year-over-year basis. During the same period last year, the company earned $1.07 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 6.54 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th were issued a $0.40 dividend. The ex-dividend date was Thursday, July 28th. This represents a $1.60 annualized dividend and a dividend yield of 3.34%. Pfizer’s dividend payout ratio (DPR) is presently 31.31%.

About Pfizer

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Recommended Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.